Senseonics Holdings reported second quarter 2026 revenue of $14.5 million, a 120% year-over-year increase, driven by U.S. sales growth exceeding 150%. The company raised its full-year 2026 revenue guidance to $62–$66 million and gross margin guidance to 58–61%, citing strong commercial momentum and the integration of European operations. Q2 net loss widened to $36.7 million ($0.63 per share) from $14.5 million in the prior year, primarily due to increased R&D expenses for Gemini and Freedom programs and SG&A costs related to commercial integration. Senseonics raised more than $100 million in Q2 through equity proceeds and an expanded Hercules Capital facility, ending the quarter with $143.0 million in cash and equivalents. The company operates in the medical technology industry, designing and commercializing implantable continuous glucose monitoring systems for diabetes management.

Senseonics Holdings, Inc. announced the closing of local asset purchase agreements to acquire Eversense CGM activities in Germany, Spain, Sweden, and Italy from Ascensia Diabetes Care Holdings AG. The closings occurred on June 1 and June 8, 2026, with an effective date of June 1, 2026, for finance and accounting purposes.